The potential of BRAF-targeted therapy combined with immunotherapy in melanoma.

Abstract excerpt

Introduction: Immune checkpoint inhibitor therapy and BRAF-targeted therapy have been developed for the treatment of metastatic melanoma. The optimal use of these agents, either in sequence or combination, for the 40-50% of melanoma patients whose tumors harbor a BRAFV600 mutation is unknown, but data from a number of clinical trials, including one randomized Phase II study, are emerging.Areas covered: This...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Immune Checkpoint Inhibitors
• Share to Immunotherapy
• Share to Melanoma